After all involved legal departments finally approved the
clinical trial the first patient could come in for his injections this week. The
clinical trial aims to develop a method for guided prostate biopsy using a
Prostate Specific Membrane Antigen (PSMA) specific antibody (J591) conjugated
to a radioactive Zr89 nucleus. The standard of care is to blindly take out
between 10 and 15 biopsies of the prostate when there is reason to believe that
the patient might have neoplastic lesions, e.g. after the patient has tested
with an elevated PSA level. A guided biopsy would decrease the risk of a lesion
being missed and also allow for fewer biopsied to be made. The patients are
thus injected with the J591-Zr89 conjugate, followed by PET and MRI imaging.
After the prostate is removed it is imaged in a micro PET and micro MRI to be
able to correlate the PET signal directly to the presence of a neoplastic
lesion.
I was also trained for flow cytometry at HSS in preparation
for the TGF-beta transition experiments in the Bander Lab.
I also finally had my meeting with Dr Vahdat to discuss the
use of our GEDI chip to capture progenitor cells from breast cancer patient
blood samples. It was decided that initially primary HUVECs will be used for
capture in lieu of blood samples.
No comments:
Post a Comment